Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer

Urology. 1996 Jan;47(1):34-7. doi: 10.1016/s0090-4295(99)80378-1.

Abstract

Objectives: A number of studies have demonstrated that urokinase-type plasminogen activator (u-PA) is one of the major enzymes in the development of cancer invasion and metastasis. We examined the possibility that u-PA content is an independent prognostic marker for superficial bladder cancer.

Methods: The u-PA content was estimated in superficial bladder cancer from 52 patients undergoing transurethral resection for the first time. The survival rates of the patients were calculated and the prognostic values for u-PA content (less than 8 ng/mg protein versus more than 8 ng/mg), Stage (pTa or pT1), grade (1 and 2 versus 3), number (single versus multiple), and size (less than 1 cm versus more than 1 cm) of tumor were determined by a multivariate regression model.

Results: Development of cancer invasion and metastasis was observed in 3 and 8 patients, respectively. The survival rate of the patients with high u-PA content was significantly lower than those with low u-PA content (P < 0.005). In the multivariate regression analysis, u-PA content was the most important risk factor for the prognosis, compared with the other factors: tumor stage, grade, multiplicity, and size.

Conclusions: We have first shown that u-PA content is a new independent prognostic marker in patients with superficial bladder cancer.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Carcinoma, Transitional Cell / chemistry*
  • Carcinoma, Transitional Cell / mortality
  • Female
  • Follow-Up Studies
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Plasminogen Activators / analysis*
  • Prognosis
  • Survival Rate
  • Urinary Bladder Neoplasms / chemistry*
  • Urinary Bladder Neoplasms / mortality
  • Urokinase-Type Plasminogen Activator / analysis*

Substances

  • Plasminogen Activators
  • Urokinase-Type Plasminogen Activator